Company / SG&A Expense
REGENXBIO Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$82.9M
FY2025
5-year range
$51.8M / $88.5M
FY2021-FY2025
Trend
+8.1%
vs FY2024
Sector context
#124 of 213
Health Care
What the data says
At $83M, REGENXBIO Inc.'s sg&a expense ranks #90 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 10 years, ranging from $4M in FY2016 to $88M in FY2023.
Based on SEC 10-K filings.
$83M in FY2025 with a 5-year CAGR of +17.6%.
Improved from $88M to $83M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -1.0%
- 5-Year CAGR
- +17.6%
- 10-Year CAGR
- -
Sector benchmark
#90 of 213 in Health CareTop 42% of 213This company $82.9M Sector average $722.3M
▼
-88.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +17.6%, indicating consistent growth.
- In FY2025, sg&a expense increased 8.1% year-over-year.
- Ranks #124 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $82.9M | +8.1% |
| FY2024 | $76.6M | -13.4% |
| FY2023 | $88.5M | +3.8% |
| FY2022 | $85.3M | +64.6% |
| FY2021 | $51.8M | +40.6% |
| FY2020 | $36.9M | +35.3% |
| FY2019 | $27.2M | -26.1% |
| FY2018 | $36.9M | +35.3% |
| FY2017 | $27.2M | +607.1% |
| FY2016 | $3.9M | -29.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026